Roxadustat is the first HIF stabilizer up for FDA approval. There have been a number of roxa publications and today we took at the two most recent.

One is a pooled analysis of incident dialysis patients: roxa versus epoetin alpha. And The second is a pre-dialysis CKD study of roxa versus placebo.

Roxa represents well, but devils in the details. Join the filtrate as we go deep on roxa!

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör NephJC Team. Innehållet i podden är skapat av NephJC Team och inte av, eller tillsammans med, Poddtoppen.